JP2014114288A5 - - Google Patents

Info

Publication number

JP2014114288A5

JP2014114288A5 JP2013253745A JP2013253745A JP2014114288A5 JP 2014114288 A5 JP2014114288 A5 JP 2014114288A5 JP 2013253745 A JP2013253745 A JP 2013253745A JP 2013253745 A JP2013253745 A JP 2013253745A JP 2014114288 A5 JP2014114288 A5 JP 2014114288A5

Authority

JP

Japan

Prior art keywords

seq

patient

binding molecule

pharmaceutical composition

dose

Prior art date

2013-12-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 102000013691 Interleukin-17 Human genes 0.000 claims description 152
• 201000004681 Psoriasis Diseases 0.000 claims description 33
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 238000011282 treatment Methods 0.000 claims description 14
• 230000009885 systemic effect Effects 0.000 claims description 10
• 239000003814 drug Substances 0.000 claims description 9
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 8
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 8
• 229940079593 drug Drugs 0.000 claims description 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
• 230000037396 body weight Effects 0.000 claims description 5
• 108060003951 Immunoglobulin Proteins 0.000 claims description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
• 102000018358 immunoglobulin Human genes 0.000 claims description 4
• 229960000485 methotrexate Drugs 0.000 claims description 4
• 229960004540 secukinumab Drugs 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
• 108010036949 Cyclosporine Proteins 0.000 claims description 3
• 108010008165 Etanercept Proteins 0.000 claims description 3
• 229960005339 acitretin Drugs 0.000 claims description 3
• 229960002459 alefacept Drugs 0.000 claims description 3
• IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 3
• 239000003795 chemical substances by application Substances 0.000 claims description 3
• 229960001265 ciclosporin Drugs 0.000 claims description 3
• 229930182912 cyclosporin Natural products 0.000 claims description 3
• 229960000284 efalizumab Drugs 0.000 claims description 3
• 229960000403 etanercept Drugs 0.000 claims description 3
• 229940050411 fumarate Drugs 0.000 claims description 3
• -1 fumarate ester Chemical class 0.000 claims description 3
• 229960001743 golimumab Drugs 0.000 claims description 3
• 229960000598 infliximab Drugs 0.000 claims description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
• 229960003824 ustekinumab Drugs 0.000 claims description 3
• 238000011156 evaluation Methods 0.000 claims description 2
• 238000000034 method Methods 0.000 description 49
• 238000012423 maintenance Methods 0.000 description 22
• 230000006698 induction Effects 0.000 description 19
• 238000012546 transfer Methods 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
• 239000000710 homodimer Substances 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1